Qing Harshaw

664 total citations
27 papers, 489 citations indexed

About

Qing Harshaw is a scholar working on Oncology, Physiology and Economics and Econometrics. According to data from OpenAlex, Qing Harshaw has authored 27 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Physiology and 5 papers in Economics and Econometrics. Recurrent topics in Qing Harshaw's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Qing Harshaw is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Qing Harshaw collaborates with scholars based in United States and Switzerland. Qing Harshaw's co-authors include Carla B. Frye, Alicia C. Shillington, Richard C. Becker, Jeffrey S. Berger, Steven R. Steinhubl, Fred H. Edwards, Kathleen L. Deering, Gulshan Sharma, Vaidyanathan Ganapathy and Donald A. Mahler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Qing Harshaw

25 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Qing Harshaw United States	11	158	118	95	80	62	27	489
R.E. Roller Austria	14	96 0.6×	60 0.5×	139 1.5×	113 1.4×	38 0.6×	37	552
Shanshan Liu China	11	70 0.4×	45 0.4×	42 0.4×	60 0.8×	44 0.7×	36	450
Greta Lozano‐Ortega United States	13	93 0.6×	86 0.7×	88 0.9×	57 0.7×	15 0.2×	40	575
Muhammad Haisum Maqsood United States	13	149 0.9×	42 0.4×	92 1.0×	38 0.5×	54 0.9×	76	544
Vicente Ruiz García Spain	9	36 0.2×	106 0.9×	68 0.7×	161 2.0×	64 1.0×	23	544
Helmut L’Hoest Germany	12	69 0.4×	173 1.5×	263 2.8×	18 0.2×	38 0.6×	24	498
Armen Zakharyan United States	7	57 0.4×	173 1.5×	324 3.4×	133 1.7×	26 0.4×	14	658
Hirohisa Endo Japan	16	357 2.3×	87 0.7×	247 2.6×	108 1.4×	26 0.4×	60	716
Ralitza Parina United States	13	115 0.7×	110 0.9×	324 3.4×	14 0.2×	26 0.4×	19	532
Jonathan Kaplan United States	12	120 0.8×	51 0.4×	273 2.9×	37 0.5×	27 0.4×	32	543

Countries citing papers authored by Qing Harshaw

Since Specialization

Citations

This map shows the geographic impact of Qing Harshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qing Harshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qing Harshaw more than expected).

Fields of papers citing papers by Qing Harshaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qing Harshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qing Harshaw. The network helps show where Qing Harshaw may publish in the future.

Co-authorship network of co-authors of Qing Harshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Qing Harshaw. A scholar is included among the top collaborators of Qing Harshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qing Harshaw. Qing Harshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deering, Kathleen L., Niccole J. Larsen, Soraya Allas, et al.. (2024). Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data. Orphanet Journal of Rare Diseases. 19(1). 164–164. 5 indexed citations

Kruger, Eliza, David Yin, Nathan T. Ross, et al.. (2024). Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program. Molecular Genetics and Metabolism. 142(1). 108350–108350. 6 indexed citations

Deering, Kathleen L., Murali Sundaram, Qing Harshaw, Jeremiah Trudeau, & Jacqueline C. Barrientos. (2022). Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. PLoS ONE. 17(10). e0270291–e0270291. 5 indexed citations

Huang, Qing, Kathleen L. Deering, Qing Harshaw, & Lori A. Leslie. (2022). Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. Advances in Therapy. 39(7). 3292–3307. 10 indexed citations

Joseph, Richard W., Frank Xiaoqing Liu, Alicia C. Shillington, et al.. (2020). Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. Quality of Life Research. 29(10). 2651–2660. 18 indexed citations

Jang, Sekwon, et al.. (2020). Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. Dermatology and Therapy. 10(5). 985–999. 12 indexed citations

Huang, Qing, Kathleen L. Deering, Qing Harshaw, Tarun Bhagnani, & Lori A. Leslie. (2020). Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study. Blood. 136(Supplement 1). 16–18. 4 indexed citations

Joseph, Richard W., Frank Xiaoqing Liu, Alicia C. Shillington, et al.. (2019). Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings.. Journal of Clinical Oncology. 37(15_suppl). e21004–e21004.

Joseph, Richard W., Alicia C. Shillington, Todd A. Lee, et al.. (2019). Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics. 23(2). 132–138. 7 indexed citations

10.

Bailey, Robert A., et al.. (2018). Changing Patients’ Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. Diabetes Therapy. 9(2). 803–814. 10 indexed citations

11.

Sharma, Gulshan, et al.. (2017). Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 4(3). 217–224. 82 indexed citations

12.

Bailey, Robert A., Michael Pfeifer, Alicia C. Shillington, et al.. (2015). Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict. BMC Health Services Research. 16(1). 10–10. 64 indexed citations

13.

Narayana, Arvind, Nathaniel P. Katz, Alicia C. Shillington, et al.. (2015). National Breakthrough Pain Study. Pain. 156(2). 252–259. 31 indexed citations

14.

Harshaw, Qing, et al.. (2013). Costs associated with intravenous patient controlled analgesia (IV-PCA) in us hospitals. Value in Health. 16(3). A117–A117. 5 indexed citations

15.

Berger, Jeffrey S., et al.. (2012). Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. Journal of Thrombosis and Thrombolysis. 34(1). 56–64. 14 indexed citations

16.

Peyrot, Mark, Qing Harshaw, Alicia C. Shillington, Yunfei Xu, & R. R. Rubin. (2011). Validation of a tool to assess medication treatment satisfaction in patients with Type 2 diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ). Diabetic Medicine. 29(8). 1060–1066. 15 indexed citations

17.

Harshaw, Qing, et al.. (2010). Impact of Worsening Renal Function During Hospital Admission on Resource Utilization in Patients With Heart Failure. The American Journal of Cardiology. 106(8). 1139–1145. 17 indexed citations

18.

Miller, Bradley S., Dorothy I. Shulman, Alicia C. Shillington, et al.. (2010). Consensus and Discordance in the Management of Growth Hormone-Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices Survey. International Journal of Pediatric Endocrinology. 2010. 1–10. 7 indexed citations

19.

Berger, Jeffrey S., Carla B. Frye, Qing Harshaw, et al.. (2008). Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery. Journal of the American College of Cardiology. 52(21). 1693–1701. 127 indexed citations

20.

Patel, Bina, et al.. (2007). Success of a Comprehensive School-Based Asthma Intervention on Clinical Markers and Resource Utilization for Inner-City Children with Asthma in Chicago: The Mobile C.A.R.E. Foundation's Asthma Management Program. Journal of Asthma. 44(2). 113–118. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact